Table 2.

Baseline patient’s and procedural characteristics

	AIDA 2017		ABSORB III 2017		ABSORB China 2016		ABSORB II 2016		ABSORB Japan 2016
	BRS	EES	BRS	EES	BRS	EES	BRS	EES	BRS	EES
N of patients, n	924	921	1322	686	238	237	335	166	266	134
Age, yrs.	64	64	63	64	57	58	62	61	67	67
Male, %	72	76	71	70	72	73	76	80	79	74
Hypertension, %	51	50	85	85	59	60	69	72	78	80
Diabetes, %	18	17	31	33	25	23	24	24	36	36
Dyslipidaemia, %	38	38	86	86	42	38	75	80	82	82
Prior MI, %	18	19	21	22	17	16	28	28	16	24
STEMI, %	25		0		0		0		0
NSTEMI, %	20		0		0		0		0
UA, %	8		26		64		21		12
SA, %	40		58		19		64		64
Silent Ischaemia, %	NR		10		5		12		23
Intracoronary imaging, %	NR		100	100	0.4	0.4	100	100	100	100
Pre-dilation, %	97	91	100	100	99.6	98	100	99	100	100
Post dilation, %	74	49.1	65.5	51.2	63	54.4	61	59	82.2	77.4

yrs years, MI myocardial infarction BRS = bioresorbable vascular scaffold, EESeverolimus-eluting stent, STEMI ST-elevation myocardial infarction, NSTEMI No ST-elevation myocardial infarction;UA = unstable angina, SA stable angina, NR not reported